https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-03 / Sci Transl Med 2018 01;10(422)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-03 / Sci Transl Med 2018 01;10(422)2018-01-03 00:00:002018-01-03 00:00:00Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-692017-09-20 00:00:002019-02-15 08:36:14Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-2352017-09-01 00:00:002019-02-15 08:51:59Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e52017-08-14 00:00:002017-08-14 00:00:00Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-07 / Biomed Res Int 2017;2017:5618174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-07 / Biomed Res Int 2017;2017:56181742017-06-07 00:00:002017-06-07 00:00:00Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Neuro-oncology 2017 06;19(6):796-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Neuro-oncology 2017 06;19(6):796-8072017-06-01 00:00:002019-02-15 08:36:06Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-24 / Neurol. Med. Chir. (Tokyo) 2017 Jul;57(7):321-330
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-24 / Neurol. Med. Chir. (Tokyo) 2017 Jul;57(7):321-3302017-05-24 00:00:002019-02-15 08:36:10Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-12 / Onco Targets Ther 2017;10:2097-2106
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-12 / Onco Targets Ther 2017;10:2097-21062017-04-12 00:00:002019-02-15 08:34:49Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-01 / Cancer Control 2017 Apr;24(2):180-186
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-01 / Cancer Control 2017 Apr;24(2):180-1862017-04-01 00:00:002019-02-15 08:36:12Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-7174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-71742017-01-24 00:00:002019-02-15 08:36:13Targeting immune checkpoints in malignant glioma
